Potential policy reforms to strengthen the accelerated approval pathway

Area of Science:

• Health Policy
• Drug Regulation
• Pharmaceutical Economics

Background:

• The US FDA's accelerated approval pathway is crucial for timely access to novel therapies.
• This pathway faces increasing scrutiny over its impact on drug pricing, market access, and regulatory uncertainty.
• Balancing innovation incentives with patient safety and cost-effectiveness remains a significant challenge.

Purpose of the Study:

• To analyze key concerns surrounding the accelerated approval pathway.
• To evaluate the advantages and disadvantages of ten potential policy reforms.
• To inform strategies for strengthening the pathway within the US healthcare system.

Main Methods:

• Policy analysis of the US accelerated approval process.
• Review of existing literature on drug approval and pricing.
• Evaluation of ten proposed policy reforms, categorizing them by implementation feasibility (FDA-only vs. multi-stakeholder).

Main Results:

• Accelerated approval is central to ongoing debates on drug approvals and pricing.
• Specific reforms offer potential benefits but also present challenges.
• The analysis identifies pathways for improvement achievable through regulatory action and broader collaboration.

Conclusions:

• Strengthening the accelerated approval pathway requires careful consideration of its complex trade-offs.
• Policy reforms can enhance the balance between access, cost, and uncertainty.
• A collaborative approach involving government, payers, and the life science industry is essential for optimizing the pathway.